Theravance Biopharma Inc (TBPH.OQ)
TBPH.OQ on NASDAQ Stock Exchange Global Market
25.32USD
3:59pm EST
25.32USD
3:59pm EST
Change (% chg)
$-1.68 (-6.22%)
$-1.68 (-6.22%)
Prev Close
$27.00
$27.00
Open
$26.79
$26.79
Day's High
$26.79
$26.79
Day's Low
$25.27
$25.27
Volume
86,977
86,977
Avg. Vol
64,159
64,159
52-wk High
$35.48
$35.48
52-wk Low
$21.27
$21.27
About
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)
Overall
| Beta: | 1.81 |
| Market Cap(Mil.): | $1,496.10 |
| Shares Outstanding(Mil.): | 55.41 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TBPH.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 32.78 | 36.27 |
| EPS (TTM): | -4.72 | -- | -- |
| ROI: | -71.43 | 13.04 | 12.64 |
| ROE: | -295.61 | 14.06 | 13.67 |
Mylan and Theravance's COPD treatment gets FDA approval
Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval
Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
Mylan and Theravance Biopharma's COPD treatment gets FDA approval
Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
Estimates